These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36798006)

  • 1. Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS-441524 in patients with moderate and severe COVID-19.
    Tamura R; Irie K; Nakagawa A; Muroi H; Eto M; Ikesue H; Muroi N; Fukushima S; Tomii K; Hashida T
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):513-521. PubMed ID: 36798006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction.
    Sukeishi A; Itohara K; Yonezawa A; Sato Y; Matsumura K; Katada Y; Nakagawa T; Hamada S; Tanabe N; Imoto E; Kai S; Hirai T; Yanagita M; Ohtsuru S; Terada T; Ito I
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):94-103. PubMed ID: 34793625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
    Leegwater E; Moes DJAR; Bosma LBE; Ottens TH; van der Meer IM; van Nieuwkoop C; Wilms EB
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0025422. PubMed ID: 35647646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
    Tempestilli M; Ascoli Bartoli T; Benvenuto D; Stazi GV; Marchioni L; Nicastri E; Agrati C
    J Antimicrob Chemother; 2022 Sep; 77(10):2683-2687. PubMed ID: 35848782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.
    Avataneo V; de Nicolò A; Cusato J; Antonucci M; Manca A; Palermiti A; Waitt C; Walimbwa S; Lamorde M; di Perri G; D'Avolio A
    J Antimicrob Chemother; 2020 Jul; 75(7):1772-1777. PubMed ID: 32361744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
    Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
    Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.
    Alvarez JC; Moine P; Etting I; Annane D; Larabi IA
    Clin Chem Lab Med; 2020 Aug; 58(9):1461-1468. PubMed ID: 32573468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
    Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C;
    J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
    Deb S; Reeves AA
    J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma.
    Skaggs C; Zimmerman H; Manicke N; Kirkpatrick L
    J Mass Spectrom Adv Clin Lab; 2022 Aug; 25():27-35. PubMed ID: 35721272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.
    Corcione S; De Nicolò A; Montrucchio G; Scabini S; Avataneo V; Bonetto C; Mornese Pinna S; Cusato J; Canta F; Urbino R; Di Perri G; Brazzi L; De Rosa FG; D'Avolio A
    Br J Clin Pharmacol; 2021 Dec; 87(12):4861-4867. PubMed ID: 33990984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects.
    Abouellil A; Bilal M; Taubert M; Fuhr U
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Jan; 396(1):73-82. PubMed ID: 36123499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS-441524 in patients with COVID-19: A limited case series.
    Choe PG; Jeong SI; Kang CK; Yang L; Lee S; Cho JY; Han SS; Kim DK; Lee SM; Park WB; Oh MD; Kim NJ
    Clin Transl Sci; 2022 Mar; 15(3):732-740. PubMed ID: 34761554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum.
    Reckers A; Wu AHB; Ong CM; Gandhi M; Metcalfe J; Gerona R
    J Antimicrob Chemother; 2021 Jun; 76(7):1865-1873. PubMed ID: 33864090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
    JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats.
    Yang L; Lin IH; Lin LC; Dalley JW; Tsai TH
    EBioMedicine; 2022 Jul; 81():104095. PubMed ID: 35671622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.
    Cox RM; Wolf JD; Lieber CM; Sourimant J; Lin MJ; Babusis D; DuPont V; Chan J; Barrett KT; Lye D; Kalla R; Chun K; Mackman RL; Ye C; Cihlar T; Martinez-Sobrido L; Greninger AL; Bilello JP; Plemper RK
    Nat Commun; 2021 Nov; 12(1):6415. PubMed ID: 34741049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of GS-441524, the active metabolite of remdesivir, in patients receiving continuous renal replacement therapy: A case series.
    Nishikawa A; Ito I; Yonezawa A; Itohara K; Matsubara T; Sato Y; Matsumura K; Hamada S; Tanabe N; Kai S; Imoto E; Yoshikawa K; Ohtsuru S; Yanagita M; Hirai T; Terada T
    J Infect Chemother; 2024 Apr; 30(4):348-351. PubMed ID: 37866621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study.
    Ahmed A; Munoz FM; Muller WJ; Agwu A; Kimberlin DW; Galli L; Deville JG; Sue PK; Mendez-Echevarria A; Humeniuk R; Guo S; Rodriguez L; Han D; Hedskog C; Maxwell H; Palaparthy R; Kersey K; Rojo P;
    Pediatrics; 2024 Mar; 153(3):. PubMed ID: 38332740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.